X4 Pharmaceuticals Inc (XFOR) Stock Price, Quote & News

Company Profile

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical tri...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 529 8300

Website: www.x4pharma.com

Address:

61 North Beacon Street, 4th Floor, Boston, United States

Pope25 Jul. 7 at 3:16 PM

$XFOR sticking with $1.50 until earnings

2 · Reply

Rohtan Jul. 7 at 3:10 PM

$XFOR added heavy at 1.76 . New average 1.84

0 · Reply

jacob101 Jul. 7 at 2:40 PM

$XFOR impressive pain here, kudos Paula you’re the champ of all CEO’s 💪🌶️

0 · Reply

lilBobbyBagholder Jul. 7 at 2:18 PM

$XFOR Paula!

0 · Reply

RedToGreenMan Jul. 4 at 9:32 PM

$XFOR why the 90% drop in one year? Seems oversold 💵⚡️

2 · Reply

Rohtan Jul. 3 at 4:57 PM

$XFOR Dang. Wasn’t expecting this . Looks like I have to wait for average down.

1 · Reply

Stmkr Jul. 3 at 4:51 PM

$XFOR This is getting more and more ridiculous. 11M market cap?? Come on management. Just sell the company...

1 · Reply

The_Fudster Jul. 3 at 1:58 PM

$XFOR earth to Paula?

1 · Reply

Gunnar1 Jul. 3 at 5:39 AM

$XFOR Still oversold, but turnaround in sight? Daily chart, let's break EMA5 and 10 for consolidation at mid 2's. After that we'll see...

1 · Reply

St0ckt0k101 Jul. 2 at 10:17 PM

$XFOR decent day Today!!! Should go back to $2.50-$2.75 range in time. It shouldn’t be this low. Keep buying the lows folks.

2 · Reply

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

Jun 10, 2025, 8:00 AM EDT - 27 days ago

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

Jun 2, 2025, 4:05 PM EDT - 4 weeks ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 14, 2025, 4:12 PM EDT - 7 weeks ago

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

May 1, 2025, 12:44 PM EDT - 2 months ago

X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript

May 1, 2025, 6:01 AM EDT - 2 months ago

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Apr 28, 2025, 7:16 AM EDT - 2 months ago

Top 3 Health Care Stocks That May Rocket Higher In April

BMY UNH

Apr 24, 2025, 8:03 AM EDT - 2 months ago

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

Apr 24, 2025, 8:00 AM EDT - 2 months ago

X4 Pharmaceuticals Announces Reverse Stock Split

Apr 23, 2025, 4:05 PM EDT - 2 months ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 25, 2025, 3:02 PM EDT - 3 months ago

X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 6:01 AM EDT - 3 months ago

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 11, 2025, 8:00 AM EDT - 4 months ago

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

Feb 19, 2025, 7:35 AM EST - 4 months ago

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

Feb 6, 2025, 7:35 AM EST - 5 months ago

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

Jan 24, 2025, 7:36 AM EST - 5 months ago

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

Jan 13, 2025, 7:35 AM EST - 6 months ago

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

Nov 14, 2024, 8:00 AM EST - 8 months ago

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

Nov 13, 2024, 9:31 PM EST - 8 months ago

X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 6:07 AM EST - 8 months ago

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 6:01 AM EST - 8 months ago

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

Oct 24, 2024, 8:00 AM EDT - 9 months ago

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

Aug 28, 2024, 8:00 AM EDT - 11 months ago

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

Aug 10, 2024, 9:30 AM EDT - 11 months ago

X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 6:01 AM EDT - 11 months ago

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Jul 2, 2024, 6:17 PM EDT - 1 year ago

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

Jun 27, 2024, 6:30 AM EDT - 1 year ago

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

Jun 24, 2024, 4:51 AM EDT - 1 year ago

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

MRK NTLA ARWR VRNA

May 29, 2024, 4:30 PM EDT - 1 year ago

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

May 13, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 9, 2024, 6:30 AM EDT - 1 year ago

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

May 7, 2024, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

Apr 30, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

Apr 29, 2024, 5:02 PM EDT - 1 year ago

X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside

Apr 29, 2024, 6:37 AM EDT - 1 year ago

US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease

Apr 29, 2024, 6:30 AM EDT - 1 year ago

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome

Apr 1, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

Mar 21, 2024, 11:35 AM EDT - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Mar 12, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024

Dec 13, 2023, 11:43 PM EST - 1 year ago

X4: Dip Following Mixed Results In Chronic Neutropenia Indication Worth Buying

Dec 9, 2023, 12:00 PM EST - 1 year ago

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

Nov 10, 2023, 8:00 AM EST - 1 year ago

X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences

Nov 9, 2023, 12:37 PM EST - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 6:01 AM EST - 1 year ago

X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates

Nov 2, 2023, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Third-Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 9, 2023

Oct 31, 2023, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome

Oct 18, 2023, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors

Sep 19, 2023, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Sep 6, 2023, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Pope25 Jul. 7 at 3:16 PM

$XFOR sticking with $1.50 until earnings

2 · Reply

Rohtan Jul. 7 at 3:10 PM

$XFOR added heavy at 1.76 . New average 1.84

0 · Reply

jacob101 Jul. 7 at 2:40 PM

$XFOR impressive pain here, kudos Paula you’re the champ of all CEO’s 💪🌶️

0 · Reply

lilBobbyBagholder Jul. 7 at 2:18 PM

$XFOR Paula!

0 · Reply

RedToGreenMan Jul. 4 at 9:32 PM

$XFOR why the 90% drop in one year? Seems oversold 💵⚡️

2 · Reply

Rohtan Jul. 3 at 4:57 PM

$XFOR Dang. Wasn’t expecting this . Looks like I have to wait for average down.

1 · Reply

Stmkr Jul. 3 at 4:51 PM

$XFOR This is getting more and more ridiculous. 11M market cap?? Come on management. Just sell the company...

1 · Reply

The_Fudster Jul. 3 at 1:58 PM

$XFOR earth to Paula?

1 · Reply

Gunnar1 Jul. 3 at 5:39 AM

$XFOR Still oversold, but turnaround in sight? Daily chart, let's break EMA5 and 10 for consolidation at mid 2's. After that we'll see...

1 · Reply

St0ckt0k101 Jul. 2 at 10:17 PM

$XFOR decent day Today!!! Should go back to $2.50-$2.75 range in time. It shouldn’t be this low. Keep buying the lows folks.

2 · Reply

Fremo80 Jul. 2 at 8:04 PM

$XFOR

1 · Reply

Fremo80 Jul. 2 at 8:04 PM

$XFOR Closed Green I can Dig it.

1 · Reply

Rohtan Jul. 2 at 2:12 PM

$XFOR time to go up above $2

1 · Reply

BioTechChap Jul. 2 at 1:46 PM

$XFOR Tutes might have heard rumors about retail traders' plans for getting a Board seat. Soon too expensive for a 5% stake.

2 · Reply

Rohtan Jul. 2 at 2:38 AM

$XFOR bullish pattern detected. It will break past $2 soon

0 · Reply

kingwoodworker Jul. 2 at 12:58 AM

$XFOR 1.96 after hours

0 · Reply

Rohtan Jul. 1 at 8:10 PM

$XFOR was expecting this to close near to 1.90. This close means there is still a selling pressure. Looks like this still can hit All time low before it goes up. I will add more in the 1.60s if it goes there

1 · Reply

Fremo80 Jul. 1 at 8:01 PM

$XFOR Sad sh%t couldnt eevn keep upward trend for a day

0 · Reply

Fremo80 Jul. 1 at 7:18 PM

$XFOR Peeps Dont let this close below

0 · Reply

Rohtan Jul. 1 at 6:07 PM

$XFOR bought more at 1.90s I am pretty confident this will blow up in coming days.

0 · Reply

809capital Jul. 1 at 2:53 PM

$XFOR the company 100% is selling shares here. The volume yesterday and today is a good indication. They can only sell up to 1.2m shares. Then the pump will come.

0 · Reply

Zkoko_Bio Jul. 1 at 9:58 AM

$XFOR This should've logically been the SP before the RS...

1 · Reply

Market Cap	10.94M
Revenue (ttm)	2.56M
Net Income (ttm)	-37.45M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,462.89%
Debt to Equity Ratio	3.30

Volume	380,000
Avg Vol	309,582
Day's Range	N/A - N/A
Shares Out	5.79M
Stochastic %K	9%
Beta	0.54
Analysts	Strong Sell
Price Target	$15.25